Drug class
ATP-sensitive potassium channel opener; antihyperinsulinaemic and vasodilator agent
Mechanism of action
Opens ATP-sensitive potassium channels in pancreatic beta cells, reducing membrane depolarisation, calcium influx and insulin secretion. In vascular smooth muscle it also causes hyperpolarisation and vasodilation.
General use cases
- Treatment of symptomatic hypoglycaemia due to hyperinsulinism in infants and children under the PROGLYCEM indication
- Treatment of hyperglycaemia associated with inoperable islet-cell tumours or selected endogenous hyperinsulinism in adults; oral and intravenous product indications are formulation-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
